{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:51:32Z","timestamp":1782323492949,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,24]]},"DOI":"10.7759\/cureus.111438","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:28:39Z","timestamp":1782322119000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Bispecific Antibodies in Relapsed or Refractory Multiple Myeloma With Extramedullary Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Oscar J","family":"Burke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Peruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimra","family":"Tul Ain Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragnan","family":"Kancharla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach","volume":"29","author":"Blad\u00e9 J","year":"2011","unstructured":"Blad\u00e9 J, Fern\u00e1ndez de Larrea C, Rosi\u00f1ol L, Cibeira MT, Jim\u00e9nez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011, 29:3805-12. 10.1200\/JCO.2011.34.9290","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.740562","article-title":"Extramedullary multiple myeloma","volume":"54","author":"Weinstock M","year":"2013","unstructured":"Weinstock M, Ghobrial IM. Extramedullary multiple myeloma. Leuk Lymphoma. 2013, 54:1135-41. 10.3109\/10428194.2012.740562","journal-title":"Leuk Lymphoma"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary multiple myeloma","volume":"34","author":"Bhutani M","year":"2020","unstructured":"Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia. 2020, 34:1-20. 10.1038\/s41375-019-0660-0","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024590","article-title":"Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma","volume":"144","author":"John M","year":"2024","unstructured":"John M, Helal M, Duell J, et al.. Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma. Blood. 2024, 144:2121-35. 10.1182\/blood.2024024590","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani SZ","year":"2012","unstructured":"Usmani SZ, Heuck C, Mitchell A, et al.. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012, 97:1761-7. 10.3324\/haematol.2012.065698","journal-title":"Haematologica"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.094409","article-title":"Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse","volume":"99","author":"Pour L","year":"2014","unstructured":"Pour L, Sevcikova S, Greslikova H, et al.. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014, 99:360-4. 10.3324\/haematol.2013.094409","journal-title":"Haematologica"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni M","year":"2010","unstructured":"Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010, 21:325-30. 10.1093\/annonc\/mdp329","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06705-3","article-title":"Outcomes in patients with relapsed\/refractory multiple myeloma with extramedullary disease: a meta-analysis","volume":"104","author":"Voorhees PM","year":"2025","unstructured":"Voorhees PM, Kumar S, Usmani SZ, et al.. Outcomes in patients with relapsed\/refractory multiple myeloma with extramedullary disease: a meta-analysis. Ann Hematol. 2025, 104:6263-74. 10.1007\/s00277-025-06705-3","journal-title":"Ann Hematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau P","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NW, et al.. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022, 387:495-505. 10.1056\/NEJMoa2203478","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023616","article-title":"Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies","volume":"144","author":"Touzeau C","year":"2024","unstructured":"Touzeau C, Krishnan AY, Moreau P, et al.. Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies. Blood. 2024, 144:2375-88. 10.1182\/blood.2023023616","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin AM","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, et al.. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023, 29:2259-67. 10.1038\/s41591-023-02528-9","journal-title":"Nat Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma N","year":"2024","unstructured":"Bumma N, Richter J, Jagannath S, et al.. Linvoseltamab for treatment of relapsed\/refractory multiple myeloma. J Clin Oncol. 2024, 42:2702-12. 10.1200\/JCO.24.01008","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari A","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, et al.. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022, 387:2232-44. 10.1056\/NEJMoa2204591","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar S","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al.. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016, 17:e328-46. 10.1016\/S1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"key":"ref16","unstructured":"National Heart, Lung, and Blood Institute. Study quality assessment tools. Quality assessment tool for case series studies. (2021). Accessed. June 15, 2026: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514752","article-title":"Dual targeting of extramedullary myeloma with talquetamab and teclistamab","volume":"394","author":"Kumar S","year":"2026","unstructured":"Kumar S, Mateos MV, Ye JC, et al.. Dual targeting of extramedullary myeloma with talquetamab and teclistamab. N Engl J Med. 2026, 394:51-61. 10.1056\/NEJMoa2514752","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee H","year":"2023","unstructured":"Lee H, Ahn S, Maity R, et al.. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023, 29:2295-306. 10.1038\/s41591-023-02491-5","journal-title":"Nat Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/505353-efficacy-of-bispecific-antibodies-in-relapsed-or-refractory-multiple-myeloma-with-extramedullary-disease-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:28:45Z","timestamp":1782322125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/505353-efficacy-of-bispecific-antibodies-in-relapsed-or-refractory-multiple-myeloma-with-extramedullary-disease-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.111438","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,24]]}}}